Cart
sales@molnova.com
Clazosentan
CAS No. 180384-56-9
Clazosentan( —— )
Catalog No. M35762 CAS No. 180384-56-9
Clazosentan (Ro 61-1790) is a selective antagonist of the endothelin A receptor (ETAreceptor) that inhibits ET-1-mediated vasoconstriction, preventing cerebral vasospasm and vasospasm-associated cerebral infarction.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 128 | Get Quote |
|
| 5MG | 188 | Get Quote |
|
| 10MG | 330 | Get Quote |
|
| 25MG | 701 | Get Quote |
|
| 50MG | 1132 | Get Quote |
|
| 100MG | 1431 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameClazosentan
-
NoteResearch use only, not for human use.
-
Brief DescriptionClazosentan (Ro 61-1790) is a selective antagonist of the endothelin A receptor (ETAreceptor) that inhibits ET-1-mediated vasoconstriction, preventing cerebral vasospasm and vasospasm-associated cerebral infarction.
-
DescriptionClazosentan (Ro 61-1790) is a selective endothelin A (ETA) receptor antagonist. Clazosentan inhibits ET-1-mediated vasoconstriction. Clazosentan prevents cerebral vasospasm, vasospasm-related cerebral infarction.
-
In VitroClazosentan (0.1 μM) inhibits the ETA receptor in cerebral arteries.Clazosentan is a substrate of the organic anion-transporting polypeptide (OATP) 1B1/1B3.
-
In VivoClazosentan (10 μM, 0.05?mL/kg, intracisternal injection) inhibits the contractile responses to ET-1 in rats.Clazosentan (10 mg/kg, s.c.) inhibits IL-33-induced hypernociception in mice.Animal Model:RatsDosage:10 μM, 0.05?mL/kg Administration: Intracisternal injection Result:Inhibited the contractile responses to ET-1, without preventing SAH-induced upregulation of ET receptors in cerebral arteries.
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetEndothelin Receptor
-
RecptorEndothelin Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number180384-56-9
-
Formula Weight577.57
-
Molecular FormulaC25H23N9O6S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 83.33 mg/mL (144.28 mM; Ultrasonic )
-
SMILESCOc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C)cn2)nc(nc1OCCO)-c1ccnc(c1)-c1nn[nH]n1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Juif PE, et al. Clinical Pharmacology of Clazosentan, a Selective Endothelin A Receptor Antagonist for the Prevention and Treatment of aSAH-Related Cerebral Vasospasm. Front Pharmacol. 2021 Feb 4;11:628956. ?
molnova catalog
related products
-
Zibotentan
Zibotentan (ZD4054) is a specific Endothelin (ET)A antagonist with IC50 of 21 nM, exhibiting no activity at ETB. Phase 3.
-
Ro 46-2005
Ro 46-2005 is the first synthetic orally active nonpeptide antagonist of endothelin receptor with equipotent potency (IC50=0.2-0.5 uM) for ETA and ETB.
-
SB-209670
SB-209670 is a selective endothelin receptor antagonist that inhibits the activity of ET(B) receptors in rat vascular endothelium and vascular smooth muscle.
